Accelerator™ Drug Development By Thermo Fisher Scientific

As drug development grows more complex, risk accumulates at every stage — often magnified when smaller biotech companies are left coordinating multiple vendors across drug substance, drug product, analytics, and clinical operations. In this video, Thermo Fisher Scientific experts explain how an accelerated, integrated model addresses that challenge through connected expertise, shared governance, and seamless execution.

The core message: don't optimize for the next milestone — optimize for the full journey. Making the right decisions early, with the right partners, reduces downstream risk and avoids costly delays. That means planning around scalable, well-controlled manufacturing from the outset, defining a clear development strategy, and aligning regulatory and supply chain timelines from day one.

The experts highlight how partnering with a single provider across clinical research (via CRO PPD), manufacturing, and clinical supply gives sponsors an integrated risk register, improved data flow, and tighter cross-functional alignment. Underpinning it all is technology that acts as a digital backbone across the CDMO and CRO space — enabling end-to-end data continuity, reducing silos, and shifting teams from reactive troubleshooting to proactive risk mitigation.